Teva Pharmaceutical Industries Ltd. has appointed Timothy R. Wright to the company’s executive leadership team, heading business development, strategy and innovation. In this new role, Mr. Wright will be responsible for identifying new sources of innovation and growth that are extensions of Teva’s business model. Mr. Wright's appointment will be effective April 13, 2015, and he will report directly to the President and CEO, Erez Vigodman.
Mr. Wright has almost 30 years of global experience in pharmaceuticals and biotech with a career that has included such roles as chief executive officer, head of business development and strategy and head of global operations, and has worked extensively in partnership with academia. Most recently, he was the Director of the Drug Discovery and Development Institute at The Ohio State University Comprehensive Cancer Center, where he conceptualized and operationalized the institute, and established external networks that served to accelerate drug development activities and created partnerships among pharmaceutical companies that worked to augment development. Mr. Wright has also served previously as President of Covidien Pharmaceuticals from 2007-2010, where among other key achievements; he delivered year-over-year improvement in revenue growth, gross margin expansion, operating income and return on invested capital. He was CEO (Interim) & President, a member of the Board of Directors and Chief Operating Officer (2004-2007) at AAI Pharmaceuticals/Xanodyne. He also held roles at Elan Pharmaceuticals, President, Global Operations (2001 – 2004) and President, Europe, Japan & ROW, Executive Vice President, Business Development & Licensing (2001 – 2002); DuPont Merck Pharmaceutical Company (where he worked from 1984 – 1999) and held roles such as Senior Vice President, Strategy & Corporate Business Development (1996 – 1999), Vice President, Strategic Marketing & Operations – Europe (1995 – 1996).
Source: Teva Pharmaceutical Industries